Disseminated growth of myeloma tumors is regulated by heparanase and syndecan-1

被引：0
|
作者：
Khotskaya, Yekaterina
Suva, Larry
Sanderson, Ralph
机构：
[1] Univ Alabama Birmingham, Birmingham, AL USA
[2] Univ Arkansas Med Sci, Little Rock, AR 72205 USA
来源：
CANCER RESEARCH | 2009年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4945
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma.
    Mahtouk, Karene
    Hose, Dirk
    Reme, Thierry
    Hundemer, Michael
    Jourdan, Michel
    Jourdan, Eric
    Pantesco, Veronique
    Baudard, Marion
    De Vos, John
    Larroque, Marion
    Moehler, Thomas
    Rossi, Jean-Francois
    Goldschmidt, Hartmut
    Klein, Bernard
    BLOOD, 2006, 108 (11) : 999A - 999A
  • [42] Syndecan-1 is essential for the myeloma cell growth factor activity of EGF-family ligands in multiple myeloma.
    Mahtouk, K
    Cremer, FW
    Rème, T
    Jourdan, M
    Baudard, M
    Moreaux, M
    Requirand, G
    Fiol, G
    De Vos, J
    Moos, M
    Quittet, P
    Goldschmidt, H
    Rossi, JF
    Hose, D
    Klein, B
    BLOOD, 2005, 106 (11) : 186A - 186A
  • [43] Effects Of Dalteparin On The Heparanase/Syndecan-1 Axis In a Randomized Phase 2 Clinical Trial Of Patients With Treatment-Naive Multiple Myeloma
    Ailawadhi, Sikander
    Liebman, Howard A.
    Groshen, Susan
    Tsao-Wei, Denice D.
    Rochanda, Leanne
    Aldoss, Ibrahim
    O'Connell, Casey
    Wang, Teresa
    Duran, Christine
    Rickles, Frederick
    BLOOD, 2013, 122 (21)
  • [44] Can syndecan-1 become a prognostic factor in solid tumors?
    Oguri, K
    Okayama, M
    JOURNAL OF GASTROENTEROLOGY, 2004, 39 (02) : 197 - 199
  • [45] Can syndecan-1 become a prognostic factor in solid tumors?
    Kayoko Oguri
    Minoru Okayama
    Journal of Gastroenterology, 2004, 39 : 197 - 199
  • [46] Disruption of the Syndecan-1/Integrin Axis is a Novel Target for Myeloma Therapy
    Yang, Y.
    Ritchie, J. P.
    Ell, B.
    Rapraeger, A. C.
    Sanderson, R. D.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2008, 23 : S64 - S64
  • [47] Role of syndecan-1 in TRAIL-induced apoptosis in myeloma cells
    Wu, Yung-Hsuan
    Yang, Chen-Ying
    Chien, Wen-Li
    Lin, Kuo-I
    Lai, Ming-Zong
    JOURNAL OF IMMUNOLOGY, 2012, 188
  • [48] Transcriptional regulation of syndecan-1 expression by growth factors
    Jaakkola, P
    Jalkanen, M
    PROGRESS IN NUCLEIC ACID RESEARCH AND MOLECULAR BIOLOGY, VOL 63, 2000, 63 : 109 - 138
  • [49] Serum syndecan-1: a new independent prognostic marker in multiple myeloma
    Seidel, C
    Sundan, A
    Hjorth, M
    Turesson, I
    Dahl, IMS
    Abildgaard, N
    Waage, A
    Borset, M
    BLOOD, 2000, 95 (02) : 388 - 392
  • [50] The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy
    Yang, Yang
    MacLeod, Veronica
    Dai, Yuemeng
    Khotskaya-Sample, Yekaterina
    Shriver, Zachary
    Venkataraman, Ganesh
    Sasisekharan, Ram
    Naggi, Annamaria
    Torri, Giangiacomo
    Casu, Benito
    Vlodavsky, Israel
    Suva, Larry J.
    Epstein, Joshua
    Yaccoby, Shmuel
    Shaughnessy, John D., Jr.
    Barlogie, Bart
    Sanderson, Ralph D.
    BLOOD, 2007, 110 (06) : 2041 - 2048
12345